Special Phage Holdings wins NSW commercialisation award

BIO 2008, the world's largest conference for the biotechnology industry, is being held in San Diego from June 16. In our annual preview, we take a look at how the Australian sector is travelling.

Biotechs crunchy, Mesoblast keen, LabTech launches and NeuroDiscovery averts pain.

Progen goes into Phase III and ChemGenex Phase II, Bionomics looks at anxiety, Clinuvel gets orphan designation and Avexa announces collaboration and good results.

Adelaide biotechs vivoPharm and TGR expand and contract.

With AusBiotech 2007 being held in Brisbane next week, ALS takes its bi-annual survey of the state of the industry.

Pharma market to double in value but more needs to be spent on R&D and less on sales and marketing - PwC report.

Last year wasn't the best on record for the Australian biotechnology industry but this year and the next look much more promising. Share prices are up, investors are showing more interest and there are a lot of good stories to tell and sell.

NSW is running its annual BioFirst commercialisation awards again, offering cash and advice for local biotechs.

It hasn't been the best year on record for the Australian biotechnology industry but things should improve somewhat next year. Kate McDonald reports that the fragility of the sector is sure to be a topic of discussion at this year's AusBiotech conference.